
Getting patients to engage with educational social media postings can be tricky for clinicians. Here, a young clinician shares how consistent yet fun content can help.
Research recently presented at the American College of Cardiology’s (ACC) 71st Annual Scientific Session showed that a significant amount of hypertension-related information on the popular video sharing app TikTok is not presented by qualified health care professionals. The study, "Evaluating hypertension-related content on TikTok: A social media analysis," was conducted by Nanda Siva, a third-year medical student at West Virginia University School of Medicine, and fellow medical students from West Virginia University and The George Washington University who were mentored by Arka Chatterjee, MD, associate professor of medicine at the University of Arizona. Siva, who presented the study's findings at ACC 2022, talked to Patient Care Online and highlighted a few interesting results as well as potenial solutions to combat health misinformation on social media.
FDA Approves First Oral GLP-1 Receptor Agonist for Chronic Weight Management
December 23rd 2025The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
December 19th 2025Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.
FDA Approves First Oral GLP-1 Receptor Agonist for Chronic Weight Management
December 23rd 2025The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
December 19th 2025Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.
2 Commerce Drive
Cranbury, NJ 08512